Free Trial
NASDAQ:ALZN

Alzamend Neuro (ALZN) Stock Price, News & Analysis

Alzamend Neuro logo
$2.20 -0.05 (-2.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.19 -0.01 (-0.45%)
As of 08/1/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alzamend Neuro Stock (NASDAQ:ALZN)

Key Stats

Today's Range
$2.06
$2.28
50-Day Range
$2.20
$5.44
52-Week Range
$2.06
$135.54
Volume
101,989 shs
Average Volume
234,197 shs
Market Capitalization
$6.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$180.00
Consensus Rating
Buy

Company Overview

Alzamend Neuro Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

ALZN MarketRank™: 

Alzamend Neuro scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alzamend Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alzamend Neuro has received no research coverage in the past 90 days.

  • Read more about Alzamend Neuro's stock forecast and price target.
  • Earnings Growth

    Earnings for Alzamend Neuro are expected to decrease in the coming year, from ($1.68) to ($1.71) per share.

  • Price to Book Value per Share Ratio

    Alzamend Neuro has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Alzamend Neuro's valuation and earnings.
  • Percentage of Shares Shorted

    3.16% of the float of Alzamend Neuro has been sold short.
  • Short Interest Ratio / Days to Cover

    Alzamend Neuro has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alzamend Neuro has recently increased by 2.30%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alzamend Neuro does not currently pay a dividend.

  • Dividend Growth

    Alzamend Neuro does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.16% of the float of Alzamend Neuro has been sold short.
  • Short Interest Ratio / Days to Cover

    Alzamend Neuro has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alzamend Neuro has recently increased by 2.30%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Alzamend Neuro has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Alzamend Neuro this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for ALZN on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alzamend Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $627,895.00 in company stock.

  • Percentage Held by Insiders

    30.21% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alzamend Neuro's insider trading history.
Receive ALZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.

ALZN Stock News Headlines

This Social Security Shift Could Boost Benefits by 400%
If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.
Alzamend Neuro Increases Common Stock Through Conversion
See More Headlines

ALZN Stock Analysis - Frequently Asked Questions

Alzamend Neuro's stock was trading at $10.44 at the beginning of 2025. Since then, ALZN shares have decreased by 78.9% and is now trading at $2.20.

Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings data on Monday, March, 10th. The company reported ($1.71) earnings per share for the quarter, topping the consensus estimate of ($2.61) by $0.90.

Alzamend Neuro shares reverse split on the morning of Tuesday, July 16th 2024.The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Alzamend Neuro (ALZN) raised $12 million in an initial public offering on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager.

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alzamend Neuro investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Predictive Oncology (POAI), AST SpaceMobile (ASTS), NIO (NIO) and Ford Motor (F).

Company Calendar

Last Earnings
3/10/2025
Today
8/01/2025
Next Earnings (Estimated)
9/10/2025
Fiscal Year End
4/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALZN
CIK
1677077
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$180.00
Low Price Target
$180.00
Potential Upside/Downside
+8,081.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.51 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-181.34%
Return on Assets
-116.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.58
Quick Ratio
6.58

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.95 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
2,900,000
Free Float
559,000
Market Cap
$6.38 million
Optionable
No Data
Beta
-0.32
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ALZN) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners